Index. Note: Page numbers of article titles are in boldface type.
|
|
- Damian Ford
- 5 years ago
- Views:
Transcription
1 Cardiol Clin 24 (2006) Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial infarction volume-related outcomes in cardiac catheterization laboratory and, ADMIRAL trial, 182 ADVANCE trial, 184 American College of Cardiology/American Heart Association recommendations for coronary intravascular ultrasound, American College of Cardiology/American Heart Association task force on lesion morphology, , 155 AMIGO trial, 203 Angina CABG vs. percutaneous coronary interventions for, Angiography quantitative coronary Angioplasty balloon cutting, 205 FXminiRAIL, 206 excimer laser coronary, 206 AngioSculpt scoring balloon, Angio-Seal closure device, 281, 282 ANTHEM-TIMI trial, 191 Anticoagulant(s) in PCI, direct thrombin inhibitors, LMWH, UFH, Antiplatelet agents in PCI, 186 abciximab, aspirin, eptifibatide, platelet ADP receptor antagonists, platelet glycoproteiniib/iiia receptor antagonists, 180 tirofiban, Antithrombotic therapy in PCI, See also specific agents, e.g., Antiplatelet agents, in PCI. anticoagulants, antiplatelet agents, 186 clinical trials of, acronyms for trial names, fondaparinux, novel agents, ARMYDA-2 trial, 179 Artery(ies) anatomy of normal, 163 ASPIRE trial, Aspirin in PCI, Atherectomy, directional coronary, rotational, Atherosclerosis described, 201 treatment of PCI related, Atherotomy, /06/$ - see front matter Ó 2006 Elsevier Inc. All rights reserved. doi: /s (06) cardiology.theclinics.com
2 300 INDEX B Balloon angioplasty cutting, 205 FXminiRAIL, 206 BAT trial, 190 Biolimus A-9-eluting stent, 224 C CABG. See Coronary artery bypass grafting (CABG). CACHET trial, 190 CADILLAC trial, 182 CAPTURE trial, 181 Cardiac catheterization laboratory quality in described, 287 identification of, 287 quality management in volume-related outcomes related to, acute myocardial infarction experience with, current experience with, described, 288 longitudinal studies, PTCA and, 289 surgical experience with, CHARISMA trial, 180 Chito-Seal pad in vascular closure, 278 Chronic total coronary occlusions (CTOs), histopathology of, 248 treatment of indications for, non-guidewire novel devices in, 251 outcomes of, 252 patient selection for, 248 techniques in, 251 CLASSICS trial, 177 Clopidogrel in PCI, Closure devices vascular, See also Vascular closure devices. Coronary angiography quantitative Coronary angioplasty excimer laser, 206 Coronary artery(ies) left main evaluation of intravascular ultrasound in, 165 Coronary artery bypass grafting (CABG), 255 percutaneous coronary interventions vs. implications in patient management, 262 in angina patients, randomized trials comparing limitations of, stenting vs., Coronary bifurcation lesions, anatomic classification of, guiding catheter in selection of, 236 impossible side branch access, isolated ostial lesions involving mail vessel or side branch, 233 of main vessel, 234 of side branch, stents for crush technique, culottes technique, future directions in, implantation of lesion preparation for, number of, one stent by intention to treat, pharmacotherapy with, 244 reverse crush technique, 242 simultaneous kissing stents technique, T technique, 242 two stents by intention to treat, 237 V stent technique, 237 Y technique, 243 Coronary occlusion total, 157 CREDO trial, 177, 180 CRUISE trial, 188 C-SIRIUS trial, 219 CTOs. See Chronic total coronary occlusions (CTOs).
3 INDEX 301 CURE trial, 177, 178 Cutting balloon angioplasty, 205 D Debulking devices, Degenerated saphenous vein grafts, DESIRE trial, 203 Direct thrombin inhibitors in PCI, Directional coronary atherectomy, DISPERSE-2 phase II trial, Distal protection devices, Doppler ultrasound intracoronary 161 Drug-eluting stents, cost-effectiveness of, 226 durable polymer, paclitaxel-eluting stents, failed or minimally effective, ongoing programs, outstanding issues related to, restenosis after predictors of, 226 sirolimus-eluting stents, thrombosis related to, D-Stat products in vascular closure, 278 Duett closure device, E EDRES trial, 204 Endeavor trials, 223 EPIC trial, 181 EPILOG trial, , 188 EPISTENT trial, 181, 186, 188 Eptifibatide in PCI, E-SIRIUS trial, 218 ESPRIT trial, 183, 186 Everolimus-eluting durable polymer stent, 224 Excimer laser coronary angioplasty, 206 F FANTASTIC study, 177 FFR. See Fractional flow reserve (FFR). Fondaparinux in PCI, Fractional flow reserve (FFR) in lesion severity evaluation, 161 FXminiRAIL balloon angioplasty, 206 H HELVETICA trial, 189 Heparin(s) LMWH in PCI, UFH in PCI, HORIZONS trial, 190 I IABP. See Intra-aortic balloon pump (IABP). IMPACT-II trial, 183 Impella CardioSystems, complications of, contraindications to, 272 described, 6 7 hemodynamic effects of, 273 implantation of, INTERACT trial, 188 Intra-aortic balloon pump (IABP), 266 Intracoronary ultrasound Doppler in lesion severity evaluation, Intravascular ultrasound American College of Cardiology/American Heart Association recommendations for, arterial measurements by, 163 complications of assessment of, for stent restenosis, 170 for stenting guidance, future of, in coronary lesion evaluation, in left main coronary artery evaluation, 165
4 302 INDEX Intravascular (continued) in percutaneous coronary interventions era, See also Percutaneous coronary interventions, intravascular ultrasound in era of. vulnerable plaque identification with, ISAR diabetes trial, 222 ISAR-2 trial, 182 ISAR-DESIRE trial, ISAR-REACT trial, 179, 182 ISAR-SWEET trial, 181 J JUMBO-TIMI 26 trial, 179 L Laser therapy, Left main coronary artery evaluation of intravascular ultrasound in, 165 Left ventricular assist devices (LVADs), See also specific types, e.g., TandemHeart IABP, 266 Impella CardioSystems, intra-aortic balloon pump, 266 TandemHeart, Lesion(s) angulated, 154 bifurcation, 154 calcification of, classification of, degenerated saphenous vein grafts, eccentric, 156 inaccessible, 156 irregular, 156 long, 156 morphology of American College of Cardiology/American Heart Association task force on, , 155 ostial, 157 severity of evaluation of, LMWH. See Low molecular weight heparin (LMWH). Low molecular weight heparin (LMWH) in PCI, LVADs. See Left ventricular assist devices (LVADs). M Myocardial infarction acute volume-related outcomes in cardiac catheterization laboratory and, N NICE-1 trial, 188 P Paclitaxel derivative-eluting polymeric sleeve, 225 Paclitaxel spray stents, Paclitaxel-eluting stents durable, polymer, PARAGON trials, 186 Patch(es) vascular closure related, PCI. See Percutaneous coronary interventions (PCIs). PCI-CURE trial, 180 Perclose Prostar in vascular closure, Percutaneous coronary interventions (PCIs), , See also specific types AngioSculpt scoring balloon, antithrombotic therapy in, See also specific agents, e.g., Antiplatelet agents, in PCI. atherectomy, atherotomy, CABG vs. implications in patient management, 262 in angina patients, randomized trials comparing limitations of, cutting balloon angioplasty, 205 debulking devices, directional coronary atherectomy, distal protection devices, excimer laser coronary angioplasty, 206 FXminiRAIL balloon angioplasty, 206 history of,
5 INDEX 303 intravascular ultrasound in era of, See also Intravascular ultrasound. laser therapy, LVADs, rotational atherectomy, SilverHawk System, thrombectomy devices, Percutaneous transluminal coronary angioplasty (PTCA) volume-related outcomes in cardiac catheterization laboratory and, 289 PISCES program, Platelet(s) biology of, 175 Platelet ADP receptor antagonists in PCI, Platelet glycoproteiniib/iiia receptor antagonists in PCI, 180 PRISM-PLUS trial, 184 PROXIMATE-TIMI 27 trial, 191 PTCA. See Percutaneous transluminal coronary angioplasty (PTCA). PURSUIT trial, 182 Q Quality management in cardiac catheterization laboratory volume-related outcomes related to, See also Cardiac catheterization laboratory, quality management in, volume-related outcomes related to. Quantitative coronary angiography R RAPPORT trial, 182 RAVEL trial, 218 REALITY trial, 222 REPLACE-1 trial, 190 REPLACE-2 trial, 190 RESTORE trial, 184 Rotational atherectomy, S Saphenous vein grafts degenerated, Scion Clo-Syr P.A.D. in vascular closure, 278 Sealant closure devices, 281 SilverHawk System, SIRIUS registries and subset analyses, SIRIUS trial, 218 Sirolimus-eluting stents, SIRTAX trial, 222 SPORT trial, 204 Staple-mediated closure device, STEEPLE trial, 188 Stent(s) actinomycin D-eluting, 224 Biolimus A-9-eluting, 224 drug-eluting, See also Drug-eluting stents. everolimus-eluting durable polymer, 224 for coronary bifurcation lesions, See also Coronary bifurcation lesions, stents for. paclitaxel spray, paclitaxel-eluting durable, polymer, restenosis of intravascular ultrasound for, 170 sirolimus-eluting, Stenting CABG vs., intravascular ultrasound in, Suture-mediated closure devices, 278 SYNERGY trial, 189 Syveck Patch in vascular closure, T TandemHeart, applications of, 270 complications of, contraindications to, 268 described, explantation of, 269 hemodynamic effects of, 269 implantation of, subsystems of, TARGET trial, 185 TAXI trial, 222
6 304 INDEX TandemHeart (continued) TAXUS registries and subset analyses, TAXUS-I trial, 220 TAXUS-II trial, 220 TAXUS-III trial, 220 TAXUS-IV trial, TAXUS-V trial, 221 TAXUS-VI trial, 221 Thienopyridine antiplatelet agents in PCI, Thrombectomy devices, Thrombin inhibitors direct in PCI, Thrombosis(es) drug-eluting stents and, Thrombus(i), Ticlopidine in PCI, 177 Tirofiban in PCI, Total coronary occlusion, 157 TRITON-TIMI 38 trial, 179 U UFH. See Unfractionated heparin (UFH). Ultrasound Doppler intracoronary in lesion severity evaluation, intravascular in percutaneous coronary interventions era, See also Intravascular ultrasound. Unfractionated heparin (UFH) in PCI, V Vascular closure devices, Angio-Seal, 281 complications associated with, 285 Duett, patches, Perclose Prostar, sealant closure devices, 281 staple-mediated, suture-mediated, 278 Vasoseal, 281, 283 X-Site suture, Vasoseal closure device, 281, 283 Vein grafts saphenous degenerated, X XaNADU-ACS trial, 191 X-Site suture closure device in vascular closure,
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More information54B Subject Index - Innovation in Intervention: i2 Summit 2007J jacc March 6, 2007
54B Subject Index - Innovation in Intervention: i2 Summit 2007J jacc March 6, 2007 Subject Index Ablation-catheter Adenosine Adverse Events/cardiovascular care Predictors of Major Vascular Complications
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationPeripheral and Cardiology Coder 2018
Peripheral and Cardiology Coder 2018 Cardiovascular Services and Procedures Prepared and Published By: MedLearn Publishing A Division of MedLearn Media, Inc. 445 Minnesota Street, Suite 514 St. Paul, MN
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationDiagnostic & Therapeutic Cardiac Catheterization Coder 2017
Diagnostic & Therapeutic Cardiac Catheterization Coder 2017 Including peripheral and cardiovascular services and procedures Prepared and Published By: MedLearn Publishing A Division of Panacea Healthcare
More informationExcimer Laser for Coronary Intervention: Case Study RADIAL APPROACH: CORONARY LASER ATHERECTOMY FOR CTO OF THE LAD FOLLOWED BY PTCA NO STENTING
Excimer Laser for Coronary Intervention: Case Study RADIAL APPROACH: CORONARY LASER ATHERECTOMY FOR CTO OF THE LAD FOLLOWED BY PTCA NO STENTING 1 2013 Spectranetics. All Rights Reserved. Approved for External
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationCPT Code Details
CPT Code 93572 Details Code Descriptor Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abciximab for acute coronary syndromes, 565 567 for complication prevention, 522 for endovascular interventions, 630 for STEMI, 576 577 parenteral,
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationINTERVENTIONAL CARDIOLOGY Maintenance of Certification (MOC) Examination Blueprint
INTERVENTIONAL CARDIOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Interventional Cardiology MOC exam blueprint Based on feedback from physicians
More informationUpdate on STEMI Guidelines. Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center
Update on STEMI Guidelines Manesh R. Patel, MD Assistant Professor of Medicine Duke University Medical Center All Rights Reserved, Duke Medicine 2008 Disclosures Research Grants: NHLB, AHRQ, AstraZeneca,
More informationPCI for Bifurcation Coronary Lesion
PCI for Bifurcation Coronary Lesion Bifurcation Lesions PCI is Challenging Higher acute complication Lower success rates Higher restenosis & TLR Restenosis Rate 21 ~ 57% TLR 8 ~ 43% Event Free Survival
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationInterventional Cardiology חיים דננברג מערך הלב
Interventional Cardiology חיים דננברג מערך הלב הדסה עין-כרם History 1844- Claude Bernard. Introduced catheter through carotid artery of a horse into left ventricle to measure temperature. 1929- Werner
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationNational Intervention Council
National Intervention Council Cardiological Society of India Registry Performa for Coronary, Non- Coronary & Peripheral Interventions Period January 1st 2016 to December 31 st 2016 Dr. (Prof.) N.N. Khanna
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationGender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic
Gender-Based Outcomes in Percutaneous Coronary Intervention with Drug-Eluting Stents (from the National Heart, Lung, and Blood Institute Dynamic Registry) J. D. Abbott, et al. Am J Cardiol (2007) 99;626-31
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationA Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 1
More informationCoronary Artery Perforation Angioplasty Summit Seoul April 30, 2005
Coronary Artery Perforation Angioplasty Summit Seoul April 30, 2005 James R. Margolis, M.D. Miami International Cardiology Consultants Miami, Florida USA Introduction In the stent era, coronary artery
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ABI. See Ankle-brachial index (ABI). Afterload, deconstructing of, in ventricular vascular interaction in heart failure, 449 Air plethysmography
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationEvolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands
Evolution In Interventional Cardiology Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands 25 November 2010 Coronary Atherosclerosis Timeline in interventional cardiology Indications for
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationAccess Site Complications. Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary s Hospital Campus
Access Site Complications Nick Cheshire MD FRCS, Professor of Vascular Surgery Imperial College Healthcare St Mary s Hospital Campus Surgeons & Cardiologists Interventional Cardiology 2008 Eye of a Hawk,
More informationContemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease
Contemporary Percutaneous Coronary Intervention Versus Balloon Angioplasty for Multivessel Coronary Artery Disease A Comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationMULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
More informationInnovation by design. Technology that sets a new standard
Innovation by design Technology that sets a new standard Flexible nitinol scoring element with three rectangular spiral struts works in tandem with a semi-compliant balloon to score the target lesion Balloon
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationRadiation Safety Abbott Vascular. All rights reserved.
Radiation Safety More and more complex cases are performed Complexity Index and Fluoroscopy Time 2 3 Collimators / Distances The intensity of scattered radiation is a function of exposed field size Use
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More information2017 Cardiology Survival Guide
2017 Cardiology Survival Guide Chapter 4: Cardiac Catheterization/Percutaneous Coronary Intervention A cardiac catheterization involves a physician inserting a thin plastic tube (catheter) into an artery
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationPCI for Chronic Total Occlusions
PCI for Chronic Total Occlusions Chronic Total Occlusions Why not Medical Treatment? Medical Treatment CTO in 891 pts over 24 years High 10% Mortality Low 2 % 1 year 10 years Puma JA, et al. JACC 1994;23:390A
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationTHE CURRENT SITUATION AND FUTURE OF THE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROM IN RUSSIAN FEDERATION
: 616.127-005.8 -..,.. -...,, ( ), 2011, 581 182. 195 592 ( ) 385 590 -. 4,3 % 8,8 % ( ). 2011 62 329,, 24 931 (40 %) -. : - - ; ; 70 % ST ( ST); ST - 24. : ST,. THE CURRENT SITUATION AND FUTURE OF THE
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationPathology of Cardiovascular Interventions. Body and Disease 2011
Pathology of Cardiovascular Interventions Body and Disease 2011 Coronary Artery Atherosclerosis Intervention Goals: Acute Coronary Syndromes: Treat plaque rupture and thrombosis Significant Disease: Prevent
More informationClosure Devices. Peter F Ludman Advanced Angioplasty 2003
Closure Devices Peter F Ludman Advanced Angioplasty 2003 Where Radials fear to tread Male, 46 yrs, ACS (CK to 792) Diabetes Morbid obesity Wheel chair bound Moderate LV dysfunction, LMS and RCA disease
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationChapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials DEBDATTA BHATTACHARYYA AYAN KAR The incidence of angiographically significant left main stenosis described in various studies has
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationManual of Interventional Cardiology
782 PLATELET GLYCOPROTEIN IIb/IIIa RECEPTOR ANTAGONISTS (Tables 34.15, 34.16) Activation of the platelet glycoprotein (GP) IIb/IIIa receptor complex constitutes the final common pathway for platelet aggregation,
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACAS (Asymptomatic Carotid Atherosclerosis Study), 65 66 ACST (Asymptomatic Carotid Surgery Trial), 6 7, 65, 75 Age factors, in carotid
More informationCoronary drug-eluting stents (DES) were first approved
Thrombosis in Coronary Drug-Eluting Stents Report From the Meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health,
More informationDownloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationKurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
More informationZiyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut
Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct Professor Emory University School of Medicine Indication
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationIn the field of interventional cardiology, drug-eluting stent
Summary Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting Takahiro Nomura, 1 MD, Nobuaki Suzuki, 1
More informationINTERVENTIONAL CARDIOLOGY (Dedicated Fellowship)
INTERVENTIONAL CARDIOLOGY (Dedicated Fellowship) Director: Dr. Edward O Leary Teaching Faculty: Drs. Edward O Leary, Gregory Pavlides and Yiannis Chatzizisis A. OBJECTIVES 1. Management of patients in
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox ) No. (516/08) The Medicines Company UK Ltd 07 November 2008 The Scottish Medicines
More informationLe# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
More informationCurrent Non-Surgical Cardiac Interventions. By Pam Bayles, RN, BSN
Current Non-Surgical Cardiac Interventions By Pam Bayles, RN, BSN Balloon Angioplasty & DES A balloon-tipped catheter was first used in 1964 to treat a cause of atherosclerotic disease in a patient s leg
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationCoronary angiography and PCI
Coronary arteries Coronary angiography and PCI Samo Granda, Franjo Naji Department of Cardiology Clinical department of internal medicine University clinical centre Maribor Coronary arteries Atherosclerosis
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationhigh SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
More informationAntiplatelet therapy and Coronary Interventions. Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003
Antiplatelet therapy and Coronary Interventions Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003 Objectives Pharmacology of GP IIb/IIIa inhibitors and Monitoring of Platelet Inhibition
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Thin-Strut Drug-Eluting Stents are More Favorable for Severe Calcified Lesions After Rotational Atherectomy Than Thick-Strut Drug-Eluting Stents Yasuharu Lee, MD, Akihiro Tanaka,
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationCARDIOLOGY NEWSLETTER
CARDIOLOGY NEWSLETTER Congress and Events PCR London Valves Webcast: The ACURATE neo TAVI System, symplifying TAVI procedures Short DAPT Trial with SYNERGY BP Stent: Superior outcomes in Elderly Patients
More informationTreatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis. A Randomized Study (ATLAS)
Treatment of Saphenous Vein Bypass Grafts With Ultrasound Thrombolysis A Randomized Study (ATLAS) Mandeep Singh, MD; Uri Rosenschein, MD; Kalon K.L. Ho, MD; Peter B. Berger, MD; Richard Kuntz, MD; David
More informationA Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations
Innovative Devices : Non Stent Technologies : Drug Eluting Balloons A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations Pieter R. Stella, MD Director CardioVascular Research
More informationChapter 4 Section 9.1
Surgery Chapter 4 Section 9.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) 1.0 CPT 1 PROCEDURE CODES 33010-33130, 33140, 33141, 33361-33369, 33200-37186, 37195-37785, 92950-93272,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationClinical Outcomes in a Community-Based Single Operator Coronary Interventional Program
Clinical Outcomes in a Community-Based Single Operator Coronary Interventional Program Christian J. Posner, MD, PhD; Carol L. Kaufman, RT(R) (CV) ABSTRACT Background: Physicians who perform fewer than
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationFormation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients
Formation of and countermeasures for subacute coronary stent thrombosis in elderly diabetic patients Z.-F. Li 1, Y.-P. Zhang 2, Z.-Q. Qin 2, X.-L. Li 1, C.-H. Gao 1, S. Yang 1 and Z.-J. Chen 1 1 Department
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationCY2015 Hospital Outpatient: Endovascular Procedure APCs and Complexity Adjustments
CY2015 Hospital Outpatient: Endovascular Procedure APCs Complexity Adjustments Comprehensive Ambulatory Payment Classifications (c-apcs) CMS finalized the implementation of 25 Comprehensive APC to further
More informationDrug-Eluting Stents in Coronary CTOs Recommendations for treating patients with CTOs using new DES technology.
Drug-Eluting Stents in Coronary CTOs Recommendations for treating patients with CTOs using new DES technology. BY RAJESH M. DAVE, MD, FACC, FSCAI Coronary chronic total occlusions (CTOs) remain the most
More information